Loading...
Compugen Community
NasdaqCM:CGEN Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
Community Investing Ideas
Precision Medicine And AI Discovery Will Fuel Global Immuno-Oncology Demand
Key Takeaways Strong clinical momentum, strategic partnerships, and innovative drug discovery position Compugen to accelerate revenue growth and enhance its long-term competitive advantage. Differentiated immunotherapy pipeline and focus on precision medicine increase probability of expedited regulatory pathways and sustained high-margin commercial opportunities.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$13
87.5% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
50.98% p.a.
Profit Margin
11.27%
Future PE
203.93x
Share price in 2028
US$16.43
AI And Immunotherapy Advances Will Define Oncology's Future
Key Takeaways Partnerships with top pharmaceutical firms and a focus on innovative immunotherapies position Compugen to benefit from industry trends and expand its market reach. Advancing clinical trials and favorable regulatory momentum may enable faster drug approvals, potentially driving earlier and more stable revenue growth.Read more
1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$6.25
74.1% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
18.8% p.a.
Profit Margin
16.06%
Future PE
141.28x
Share price in 2028
US$7.9